CN110420322A - The DC vaccine for the trichina ES co-induction agent induction for preventing, treating and diagnosing for pigs trichina disease - Google Patents
The DC vaccine for the trichina ES co-induction agent induction for preventing, treating and diagnosing for pigs trichina disease Download PDFInfo
- Publication number
- CN110420322A CN110420322A CN201910742898.2A CN201910742898A CN110420322A CN 110420322 A CN110420322 A CN 110420322A CN 201910742898 A CN201910742898 A CN 201910742898A CN 110420322 A CN110420322 A CN 110420322A
- Authority
- CN
- China
- Prior art keywords
- trichinella
- cells
- vaccine
- inducer
- trichinosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940029030 dendritic cell vaccine Drugs 0.000 title claims abstract description 38
- 241000282887 Suidae Species 0.000 title abstract description 14
- 230000006698 induction Effects 0.000 title abstract description 6
- 241001439624 Trichina Species 0.000 title 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 241000243774 Trichinella Species 0.000 claims abstract description 65
- 210000004027 cell Anatomy 0.000 claims abstract description 62
- 239000000411 inducer Substances 0.000 claims abstract description 31
- 241000282898 Sus scrofa Species 0.000 claims abstract description 26
- 208000003982 trichinellosis Diseases 0.000 claims abstract description 18
- 206010044608 Trichiniasis Diseases 0.000 claims abstract description 17
- 201000007588 trichinosis Diseases 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 239000002131 composite material Substances 0.000 claims abstract description 14
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims abstract description 13
- 230000001464 adherent effect Effects 0.000 claims abstract description 13
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims abstract description 13
- 229940127093 camptothecin Drugs 0.000 claims abstract description 13
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940005608 hypericin Drugs 0.000 claims abstract description 9
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 claims abstract description 9
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000003745 diagnosis Methods 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 6
- 230000035800 maturation Effects 0.000 claims abstract description 5
- 241000546188 Hypericum Species 0.000 claims abstract description 4
- 235000017309 Hypericum perforatum Nutrition 0.000 claims abstract description 4
- 238000010276 construction Methods 0.000 claims abstract description 4
- 238000002955 isolation Methods 0.000 claims abstract description 4
- 239000002609 medium Substances 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 15
- 238000005119 centrifugation Methods 0.000 claims description 12
- 210000000813 small intestine Anatomy 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 210000001616 monocyte Anatomy 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000006285 cell suspension Substances 0.000 claims description 7
- 238000012546 transfer Methods 0.000 claims description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 6
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 6
- 238000004113 cell culture Methods 0.000 claims description 6
- 239000012091 fetal bovine serum Substances 0.000 claims description 6
- 210000005087 mononuclear cell Anatomy 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 241000243777 Trichinella spiralis Species 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000011521 glass Substances 0.000 claims description 5
- 229940096911 trichinella spiralis Drugs 0.000 claims description 5
- 230000003833 cell viability Effects 0.000 claims description 4
- 230000029087 digestion Effects 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 238000010186 staining Methods 0.000 claims description 4
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 claims description 3
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 3
- 206010048685 Oral infection Diseases 0.000 claims description 3
- 229930182555 Penicillin Natural products 0.000 claims description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 3
- 241000700157 Rattus norvegicus Species 0.000 claims description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 claims description 3
- 210000000577 adipose tissue Anatomy 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 210000003736 gastrointestinal content Anatomy 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 210000000713 mesentery Anatomy 0.000 claims description 3
- 229940049954 penicillin Drugs 0.000 claims description 3
- 210000005259 peripheral blood Anatomy 0.000 claims description 3
- 239000011886 peripheral blood Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 229960002385 streptomycin sulfate Drugs 0.000 claims description 3
- 239000008399 tap water Substances 0.000 claims description 3
- 235000020679 tap water Nutrition 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 5
- 235000015277 pork Nutrition 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 238000009169 immunotherapy Methods 0.000 abstract description 3
- 230000008676 import Effects 0.000 abstract description 2
- 210000000416 exudates and transudate Anatomy 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 description 9
- 239000008188 pellet Substances 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100022297 Integrin alpha-X Human genes 0.000 description 3
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 3
- 229960002669 albendazole Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000005684 electric field Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 210000001787 dendrite Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- DTOUWTJYUCZJQD-UJERWXFOSA-N Forsythiaside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@H](O)[C@@H](O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O1 DTOUWTJYUCZJQD-UJERWXFOSA-N 0.000 description 1
- DTOUWTJYUCZJQD-QJDQKFITSA-N Forsythiaside Natural products C[C@@H]1O[C@H](OC[C@H]2O[C@@H](OCCc3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O DTOUWTJYUCZJQD-QJDQKFITSA-N 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 241001529733 Nepeta Species 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 1
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明涉及一种用于猪旋毛虫病预防、治疗及诊断的旋毛虫ES复合诱导剂诱导的DC疫苗,属于生物技术领域。包括旋毛虫ES制备,分别加入喜树碱、金丝桃0.61μg,0.25μg,猪旋毛虫DC疫苗构建,猪外周血单核细胞的分离,贴壁细胞的获得,DC疫苗的获得。优点,利用猪外周血单核细胞,采用完全培养基利用旋毛虫ES复合制剂诱导DC成熟,对感染旋毛虫的肉食猪进行免疫治疗。采用的旋毛虫ES复合诱导剂是喜树碱和金丝桃素,可增强旋毛虫分泌物对DC细胞的诱导作用,本发明可用于预防、治疗、诊断猪旋毛虫病,提升猪肉进出口质量,保障食品安全,降低猪旋毛虫病对养猪业造成的经济损失,避免由猪旋毛虫病给食品安全及猪肉国际贸易带来的负面影响。The invention relates to a DC vaccine induced by a Trichinella ES compound inducer for the prevention, treatment and diagnosis of swine trichinosis, and belongs to the field of biotechnology. Including the preparation of Trichinella sp., adding 0.61 μg and 0.25 μg of camptothecin and hypericum respectively, the construction of porcine Trichinella DC vaccine, the isolation of porcine peripheral blood mononuclear cells, the acquisition of adherent cells, and the acquisition of DC vaccine. Advantages: The use of porcine peripheral blood mononuclear cells, the use of complete medium to induce DC maturation using the Trichinella sp. ES compound preparation, and the immunotherapy of Trichinella-infected meat-eating pigs. The Trichinella ES composite inducer is camptothecin and hypericin, which can enhance the induction effect of Trichinella exudates on DC cells. The invention can be used for preventing, treating and diagnosing pig trichinosis, and improving the quality of pork import and export. , to ensure food safety, reduce the economic losses caused by swine trichinosis to the pig industry, and avoid the negative impact of swine trichinosis on food safety and international pork trade.
Description
技术领域technical field
本发明属于生物技术领域,尤其是指用于猪旋毛虫病预防、治疗及诊断的DC疫苗。The invention belongs to the field of biotechnology, and particularly refers to a DC vaccine used for the prevention, treatment and diagnosis of swine trichinosis.
背景技术Background technique
猪旋毛虫病不仅影响人民健康,也对养猪业造成巨大的经济损失,并直接带来国际贸易的负面信誉,当前的防治形势给旋毛虫病的防治提出了新的挑战。Porcine trichinosis not only affects people's health, but also causes huge economic losses to the pig industry, and directly brings negative reputation in international trade.
随着国际肉类贸易和旅游业的发展,以及植树造林、退耕还林等生态环境的改善,加上人民生活水平提高,食品多样化以及过分的追求原生态产品等消费因素共同刺激下,近年来旋毛虫病总体上呈现出新的特点:1、食生肉习俗的地区发病率降低,而食熟肉的地区发病率升高;2、以局部暴发为主,传染源多样化。当前的防治形势给旋毛虫病的防治提出了新的挑战。阿苯哒唑用作猪饲料添加剂对猪旋毛虫病具有良好的预防作用,但是阿苯哒唑在猪肉中的药物残留问题及其副作用尚不清楚,因此暂不提倡利用驱虫药物(如阿苯哒唑)对猪进行驱虫饲养,并且国际旋毛虫委员(ICT)会也不赞成该做法。With the development of international meat trade and tourism, as well as the improvement of the ecological environment such as afforestation and returning farmland to forests, coupled with the improvement of people's living standards, food diversification and excessive pursuit of original ecological products and other consumption factors stimulated by consumption factors in recent years Trichinellosis as a whole showed new characteristics: 1. The incidence rate in areas where raw meat was customary decreased, while the incidence in areas where cooked meat was eaten increased; 2. Local outbreaks were the main source of infection. The current control situation presents new challenges to the control of trichinosis. The use of albendazole as a swine feed additive has a good preventive effect on swine trichinosis, but the drug residues and side effects of albendazole in pork are still unclear, so the use of deworming drugs (such as Albendazole) is not recommended for the time being. benpyrazole) to deworming pigs, and the International Commission on Trichinella (ICT) also disapproves of this practice.
抗原递呈细胞(Antigen.presenting cells,APC)摄取、加工和递呈抗原是启动适应性免疫反应的关键环节,树突状细胞(dendritic cell,DC)作为现今公认的体内功能最强的专职抗原递呈细胞,一方面可通过抗原递呈和分泌细胞因子启动、调控细胞免疫和T细胞依赖的特异性体液免疫反应,另一方面也可诱导调节性T细胞或清除相应的T细胞克隆而达到免疫抑制或诱导免疫耐受的作用,目前认为DC是连接天然免疫和适应性免疫的关键环节,其在维持免疫平衡中也起着至关重要的作用。近年来,随着DC疫苗应用研究的开展,DC疫苗已经成为当今备受关注的焦点之一。目前DC疫苗的类型主要有抗原致敏的DC疫苗、抗原多肽致敏的DC疫苗和基因修饰的DC疫苗等。相比前两类DC疫苗,基因修饰的DC疫苗具有较多优势,因而引起了越来越多学者的关注。尽管近年来有十几个DC疫苗处于临床Ⅲ期研究阶段,极大地激励DC疫苗的进一步开发,也表明DC疫苗具有广阔的应用前景。目前尚无利用旋毛虫ES复合制剂诱导的猪DC疫苗。Antigen presenting cells (APCs) uptake, process and present antigens are the key links in initiating adaptive immune responses. Dendritic cells (DCs) are now recognized as the most powerful professional antigens in vivo. Presenting cells, on the one hand, can initiate and regulate cellular immunity and T cell-dependent specific humoral immune responses through antigen presentation and secretion of cytokines, and on the other hand, they can also induce regulatory T cells or eliminate corresponding T cell clones. The role of immunosuppression or induction of immune tolerance, DC is currently considered to be a key link between innate immunity and adaptive immunity, and it also plays a crucial role in maintaining immune balance. In recent years, with the development of DC vaccine application research, DC vaccine has become one of the focuses of attention today. At present, the types of DC vaccines mainly include antigen-sensitized DC vaccines, antigen-polypeptide-sensitized DC vaccines, and genetically modified DC vaccines. Compared with the first two types of DC vaccines, genetically modified DC vaccines have many advantages, which has attracted more and more scholars' attention. Although more than a dozen DC vaccines are in the clinical phase III research stage in recent years, which greatly stimulates the further development of DC vaccines, it also shows that DC vaccines have broad application prospects. At present, there is no porcine DC vaccine induced by the Trichinella ES co-formulation.
发明内容SUMMARY OF THE INVENTION
本发明提供一种用于猪旋毛虫病预防、治疗及诊断的旋毛虫ES复合诱导剂诱导的DC疫苗。The invention provides a DC vaccine induced by a Trichinella ES compound inducer for the prevention, treatment and diagnosis of swine trichinosis.
本发明采取的技术方案是:包括下列步骤:The technical scheme adopted by the present invention is: comprising the following steps:
(一)、旋毛虫ES复合诱导剂制备(1) Preparation of Trichinella ES composite inducer
(1)旋毛虫ES制备(1) Trichinella ES preparation
口服感染300条旋毛虫10只Wistar大鼠颈椎脱臼法处死,取小肠,剔除脂肪组织和肠系膜,纵向剖开小肠,流动的自来水下冲洗肠内容物,取300克小肠37℃加有200U/ml青霉素和200U/ml硫酸链霉素的2000ml生理盐水中清洗小肠,人工消化法收集旋毛虫成虫并计数;将含有5万条旋毛虫成虫的液体50ml倒入一个直径15cm的干净的玻璃平皿中,静置15min,吸弃上层液体,洗净收集到的旋毛虫成虫并转移至15ml离心管中,用含有双抗的RPMI-1640培养液1000rpm/min,2min离心洗涤2遍后,将清洗后沉淀在离心管底部的旋毛虫成虫转移至25cm3的细胞培养瓶,15ml培养基,37℃,5%CO2的温箱培养12h,12h后离心,1000rpm/min,2min,收集离心上清液;反复离心上清夜,9℃,6000rpm/min,30min,浓缩至ES液体变为8-10ml无色液体,即为旋毛虫ES,将无色液体转移至1.5mL的离心管中,密封,-20℃保存;Oral infection with 300 Trichinella worms and 10 Wistar rats were sacrificed by cervical dislocation, the small intestine was removed, the adipose tissue and mesentery were removed, the small intestine was longitudinally dissected, and the intestinal contents were washed with running tap water, and 300 grams of small intestine was added with 200 U/ml at 37°C. Wash the small intestine in 2000ml of normal saline containing penicillin and 200U/ml streptomycin sulfate, collect and count the adult Trichinella worms by artificial digestion; pour 50ml of the liquid containing 50,000 adult Trichinella worms into a clean glass dish with a diameter of 15cm, Let stand for 15min, aspirate the supernatant liquid, wash the collected adult Trichinella worms and transfer them to a 15ml centrifuge tube, wash twice with RPMI-1640 medium containing double antibody at 1000rpm/min, 2min centrifugation for 2 times, and then precipitate the washed pellets. The adult Trichinella worms at the bottom of the centrifuge tube were transferred to a 25cm 3 cell culture flask, 15ml medium, 37°C, 5% CO 2 incubator for 12h, centrifuged after 12h, 1000rpm/min, 2min, and the centrifugation supernatant was collected; Repeated centrifugation of the supernatant overnight, 9°C, 6000rpm/min, 30min, concentrated until the ES liquid became 8-10ml colorless liquid, that is, Trichinella worm ES, transferred the colorless liquid to a 1.5mL centrifuge tube, sealed, -20 ℃ preservation;
(2)旋毛虫ES复合诱导剂制备(2) Preparation of Trichinella ES composite inducer
每毫升ES分别加入喜树碱、金丝桃0.61μg,0.25μg备用;0.61μg of camptothecin and hypericum were added to each ml of ES respectively, and 0.25μg was used for later use;
喜树碱、金丝桃素配置,将药物按照储存浓度配制成200mg/mL,使用时稀释至0.1ug/ml;The preparation of camptothecin and hypericin, the medicine is prepared to 200mg/mL according to the storage concentration, and diluted to 0.1ug/ml when used;
(二)、猪旋毛虫DC疫苗构建(2) Construction of porcine Trichinella DC vaccine
(1)猪外周血单核细胞的分离:(1) Isolation of porcine peripheral blood mononuclear cells:
无菌条件下采取猪前腔外静脉血10ml,吸取上层血清备用,加入等体积的PBS稀释血液,用吸管将稀释外周血14ml沿管壁徐徐加入含7ml NycoPrepTM 1.077A淋巴细胞分离液的离心管中,1800rpm离心20min,用吸管轻轻吸出离心管分离液层中的界面细胞即单个核细胞,转移至另一无菌离心管中,PBS轻轻吹打均匀,使充分稀释,1500rpm离心8min,洗涤两次,收集单核细胞;Take 10ml of pig anterior external venous blood under sterile conditions, aspirate the upper serum for later use, add an equal volume of PBS to dilute the blood, and use a pipette to slowly add 14ml of diluted peripheral blood to a centrifuge tube containing 7ml of NycoPrepTM 1.077A lymphocyte separation solution along the tube wall. medium, centrifuge at 1800rpm for 20min, gently suck out the interface cells in the centrifuge tube to separate the mononuclear cells with a pipette, transfer it to another sterile centrifuge tube, gently pipette PBS to make it fully diluted, centrifuge at 1500rpm for 8min, wash twice, to collect monocytes;
(2)贴壁细胞的获得(2) Acquisition of adherent cells
将所获的单核细胞用含10%胎牛血清的RPMll640液悬浮,吹打均匀,取10ul细胞悬液加90ul台盼蓝,充分混匀,然后加至计数盘内,进行活细胞计数,台盼蓝染色证明细胞活力>95%,The mononuclear cells obtained were suspended in RPM11640 solution containing 10% fetal bovine serum, pipetted evenly, 10ul of cell suspension was added with 90ul of trypan blue, mixed well, and then added to the counting plate for live cell counting. Hope blue staining demonstrated cell viability >95%,
计算公式:细胞数/L=4大格活细胞总数/4×104×稀释倍数Calculation formula: number of cells/L=total number of live cells in 4 large cells/4×104×dilution factor
调整单核细胞浓度为2×106个/ml,加入6孔细胞培养板中,每孔2ml,在5%CO237℃条件下孵育,90min后洗掉非贴壁细胞,加入不含FCS的RPMI1640继续孵育30min,30min后再次洗掉非贴壁细胞,所剩细胞即为贴壁的单核细胞;Adjust the concentration of monocytes to 2×10 6 cells/ml, add 2 ml per well to a 6-well cell culture plate, incubate at 37°C with 5% CO 2 , wash off non-adherent cells after 90 min, and add FCS-free cells. The RPMI1640 was incubated for 30 min, and the non-adherent cells were washed away again after 30 min, and the remaining cells were adherent monocytes;
(3)DC疫苗的获得(3) Obtaining DC vaccine
每孔加入完全培养基(重组集落刺激因子(rmGSF)160ng/ml+rmIL-4 50ng/ml+10%胎牛血清)2ml,培养板放入无菌塑料袋内,包扎袋口,细胞在5%CO2 37℃条件下培养,7天后用吸管充分洗涤培养孔,吸取细胞悬液加入离心管中,1500rpm离心8min,收集离心沉淀;完全培养基培养获得的离心沉淀,第3天换培养基,第六天加旋毛虫ES复合诱导剂5ml,第七天加TNF-α100u/ml,诱导成熟,吹打混匀,收集到的所有悬浮细胞即为猪旋毛虫DC,悬浮细胞计数,使悬浮细胞浓度为2×106个/ml,即为猪旋毛虫DC疫苗;猪每100Kg体重使用量为1ml。Add 2ml of complete medium (recombinant colony stimulating factor (rmGSF) 160ng/ml + rmIL-4 50ng/ml + 10% fetal bovine serum) to each well, put the culture plate in a sterile plastic bag, wrap the bag mouth, and place the cells at 5 Cultivated at 37°C with % CO 2 , washed the culture wells with a pipette after 7 days, sucked the cell suspension into a centrifuge tube, centrifuged at 1500 rpm for 8 min, and collected the centrifugation pellet; the centrifuged pellet obtained by culture in complete medium, the medium was changed on the third day , on the sixth day, add 5ml of Trichinella ES compound inducer, on the seventh day, add TNF-α100u/ml to induce maturation, pipetting and mixing, all the collected suspension cells are porcine Trichinella spp DC, and the suspension cells are counted to make the suspension cells The concentration is 2×10 6 /ml, that is, the pig Trichinella DC vaccine; the dosage of pig per 100Kg body weight is 1 ml.
本发明的优点,利用猪外周血单核细胞,采用完全培养基利用旋毛虫ES复合制剂诱导DC成熟,对感染旋毛虫的肉食猪进行免疫治疗。采用的旋毛虫ES复合诱导剂是通过从淫羊藿苷、鬼臼毒素、山奈酚、绿原酸、齐墩果酸、大黄素、槲皮素、连翘酯苷、喜树碱、大黄酚、靛玉红、靛蓝、金丝桃素、原花青素、荆芥油等15种中药有效成份中筛选获得,并证实喜树碱和金丝桃素可增强旋毛虫分泌物(ES)对DC细胞的诱导作用,本发明可用于预防、治疗、诊断猪旋毛虫病,提升猪肉进出口质量,保障食品安全,降低猪旋毛虫病对养猪业造成的经济损失,避免由猪旋毛虫病给食品安全及猪肉国际贸易带来的负面影响。According to the advantages of the invention, the porcine peripheral blood mononuclear cells are used, and the complete medium is used to induce DC maturation by using the Trichinella sp. ES compound preparation to perform immunotherapy on the meat-eating pigs infected with Trichinella spiralis. The trichinella ES compound inducer used is derived from icariin, podophyllotoxin, kaempferol, chlorogenic acid, oleanolic acid, emodin, quercetin, forsythiaside, camptothecin, chrysophanol , indirubin, indigo, hypericin, proanthocyanidins, nepeta oil and other 15 kinds of active ingredients of traditional Chinese medicine were screened and obtained, and it was confirmed that camptothecin and hypericin can enhance the secretion of Trichinella spiralis (ES) on DC cells. Induction, the present invention can be used to prevent, treat and diagnose swine trichinosis, improve the quality of pork import and export, ensure food safety, reduce the economic loss caused by swine trichinosis to the pig industry, and avoid the effect of swine trichinosis on food safety. and the negative impact of pork international trade.
附图说明Description of drawings
图1是ES复合诱导剂诱导的DC和未经ES复合诱导剂诱导的DC图;Figure 1 is a graph of DCs induced by ES complex inducers and DCs without ES complex inducers;
图2是ES复合诱导剂诱导的成熟DC流式鉴定图;Fig. 2 is a flow cytometric identification diagram of mature DC induced by ES compound inducer;
图3是旋毛虫ES复合诱导剂诱导DC对猪血液细胞因子的调控图;Figure 3 is a diagram showing the regulation of porcine blood cytokines by DC induced by Trichinella ES composite inducer;
图4是本发明金丝桃素浓度筛选图;Fig. 4 is the hypericin concentration screening diagram of the present invention;
图5是本发明喜树碱浓度筛选图。Fig. 5 is the screening chart of the camptothecin concentration of the present invention.
具体实施方式Detailed ways
包括下列步骤:Include the following steps:
(一)、旋毛虫ES复合诱导剂制备(1) Preparation of Trichinella ES composite inducer
(1)旋毛虫ES制备(1) Trichinella ES preparation
口服感染300条旋毛虫10只Wistar大鼠颈椎脱臼法处死,取小肠,剔除脂肪组织和肠系膜,纵向剖开小肠,流动的自来水下冲洗肠内容物,取300克小肠37℃加有200U/ml青霉素和200U/ml硫酸链霉素的2000ml生理盐水中清洗小肠,人工消化法收集旋毛虫成虫并计数;将含有5万条旋毛虫成虫的液体50ml倒入一个直径15cm的干净的玻璃平皿中,静置15min,吸弃上层液体,洗净收集到的旋毛虫成虫并转移至15ml离心管中,用含有双抗的RPMI-1640培养液1000rpm/min,2min离心洗涤2遍后,将清洗后沉淀在离心管底部的旋毛虫成虫转移至25cm3的细胞培养瓶,15ml培养基,37℃,5%CO2的温箱培养12h,12h后离心,1000rpm/min,2min,收集离心上清液;反复离心上清夜,9℃,6000rpm/min,30min,浓缩至ES液体变为8-10ml无色液体,即为旋毛虫ES,将无色液体转移至1.5mL的离心管中,密封,-20℃保存;Oral infection with 300 Trichinella worms and 10 Wistar rats were sacrificed by cervical dislocation, the small intestine was removed, the adipose tissue and mesentery were removed, the small intestine was longitudinally dissected, and the intestinal contents were washed with running tap water, and 300 grams of small intestine was added with 200 U/ml at 37°C. Wash the small intestine in 2000ml of normal saline containing penicillin and 200U/ml streptomycin sulfate, collect and count the adult Trichinella worms by artificial digestion; pour 50ml of the liquid containing 50,000 adult Trichinella worms into a clean glass dish with a diameter of 15cm, Let stand for 15min, aspirate the supernatant liquid, wash the collected adult Trichinella worms and transfer them to a 15ml centrifuge tube, wash twice with RPMI-1640 medium containing double antibody at 1000rpm/min, 2min centrifugation for 2 times, and then precipitate the washed pellets. The adult Trichinella worms at the bottom of the centrifuge tube were transferred to a 25cm 3 cell culture flask, 15ml medium, 37°C, 5% CO 2 incubator for 12h, centrifuged after 12h, 1000rpm/min, 2min, and the centrifugation supernatant was collected; Repeated centrifugation of the supernatant overnight, 9°C, 6000rpm/min, 30min, concentrated until the ES liquid became 8-10ml colorless liquid, that is, Trichinella worm ES, transferred the colorless liquid to a 1.5mL centrifuge tube, sealed, -20 ℃ preservation;
(2)旋毛虫ES复合诱导剂制备(2) Preparation of Trichinella ES composite inducer
每毫升ES分别加入喜树碱、金丝桃0.61μg,0.25μg备用;0.61μg of camptothecin and hypericum were added to each ml of ES respectively, and 0.25μg was used for later use;
喜树碱、金丝桃素配置,将药物按照储存浓度配制成200mg/mL,使用时稀释至0.1ug/ml;The preparation of camptothecin and hypericin, the medicine is prepared to 200mg/mL according to the storage concentration, and diluted to 0.1ug/ml when used;
(二)、猪旋毛虫DC疫苗构建(2) Construction of porcine Trichinella DC vaccine
(1)猪外周血单核细胞的分离:(1) Isolation of porcine peripheral blood mononuclear cells:
无菌条件下采取猪前腔外静脉血10ml,吸取上层血清备用,加入等体积的PBS稀释血液,用吸管将稀释外周血14ml沿管壁徐徐加入含7ml NycoPrepTM 1.077A淋巴细胞分离液的离心管中,1800rpm离心20min,用吸管轻轻吸出离心管分离液层中的界面细胞即单个核细胞,转移至另一无菌离心管中,PBS轻轻吹打均匀,使充分稀释,1500rpm离心8min,洗涤两次,收集单核细胞;Take 10ml of pig anterior external venous blood under sterile conditions, aspirate the upper serum for later use, add an equal volume of PBS to dilute the blood, and use a pipette to slowly add 14ml of diluted peripheral blood to a centrifuge tube containing 7ml of NycoPrepTM 1.077A lymphocyte separation solution along the tube wall. medium, centrifuge at 1800rpm for 20min, gently suck out the interface cells in the centrifuge tube to separate the mononuclear cells with a pipette, transfer it to another sterile centrifuge tube, gently pipette PBS to make it fully diluted, centrifuge at 1500rpm for 8min, wash twice, to collect monocytes;
(2)贴壁细胞的获得(2) Acquisition of adherent cells
将所获的单核细胞用含10%胎牛血清的RPMll640液悬浮,吹打均匀,取10ul细胞悬液加90ul台盼蓝,充分混匀,然后加至计数盘内,进行活细胞计数,台盼蓝染色证明细胞活力>95%,The mononuclear cells obtained were suspended in RPM11640 solution containing 10% fetal bovine serum, pipetted evenly, 10ul of cell suspension was added with 90ul of trypan blue, mixed well, and then added to the counting plate for live cell counting. Hope blue staining demonstrated cell viability >95%,
计算公式:细胞数/L=4大格活细胞总数/4×104×稀释倍数Calculation formula: number of cells/L=total number of live cells in 4 large cells/4×104×dilution factor
调整单核细胞浓度为2×106个/ml,加入6孔细胞培养板中,每孔2ml,在5%CO237℃条件下孵育,90min后洗掉非贴壁细胞,加入不含FCS的RPMI1640继续孵育30min,30min后再次洗掉非贴壁细胞,所剩细胞即为贴壁的单核细胞;Adjust the concentration of monocytes to 2×10 6 cells/ml, add 2 ml per well to a 6-well cell culture plate, incubate at 37°C with 5% CO 2 , wash off non-adherent cells after 90 min, and add FCS-free cells. The RPMI1640 was incubated for 30 min, and the non-adherent cells were washed away again after 30 min, and the remaining cells were adherent monocytes;
(3)DC疫苗的获得(3) Obtaining DC vaccine
每孔加入完全培养基(重组集落刺激因子(rmGSF)160ng/ml+rmIL-4 50ng/ml+l0%胎牛血清)2ml,培养板放入无菌塑料袋内,包扎袋口,细胞在5%CO2 37℃条件下培养,7天后用吸管充分洗涤培养孔,吸取细胞悬液加入离心管中,1500rpm离心8min,收集离心沉淀;完全培养基培养获得的离心沉淀,第3天换培养基,第六天加旋毛虫ES复合诱导剂5ml,第七天加TNF-α100u/ml,诱导成熟,吹打混匀,收集到的所有悬浮细胞,悬浮细胞计数,使悬浮细胞浓度为2×106个/ml,即为猪旋毛虫DC疫苗;猪每100Kg体重使用量为1ml。Add 2ml of complete medium (recombinant colony stimulating factor (rmGSF) 160ng/ml + rmIL-4 50ng/ml + 10% fetal bovine serum) to each well, put the culture plate into a sterile plastic bag, wrap the bag mouth, and place the cells in 5 Cultivated at 37°C with % CO 2 , washed the culture wells with a pipette after 7 days, sucked the cell suspension into a centrifuge tube, centrifuged at 1500 rpm for 8 min, and collected the centrifugation pellet; the centrifuged pellet obtained by culture in complete medium, the medium was changed on the third day , on the sixth day, add 5ml of Trichinella ES compound inducer, on the seventh day, add 100u/ml of TNF-α to induce maturation, mix by pipetting, collect all suspended cells, count the suspended cells, and make the suspended cell concentration 2×10 6 per 100Kg body weight of pigs is 1ml.
实验例1、形态学鉴定Experimental example 1. Morphological identification
1、相差倒置显微镜鉴定:每天观察细胞生长状态及形态变化,第7天拍摄细胞照片。1. Identification by phase contrast inverted microscope: cell growth state and morphological changes were observed every day, and cell photos were taken on the 7th day.
2、扫描电境鉴定:将收集的悬浮细胞离心,去2/3的上清,重新悬浮细胞;吸取细胞悬液,小心滴加在复有薄膜的玻片上,平放于培养皿中静置30min,然后在培养皿中加入2.5%的戊二醛,使玻片浸在其中,固定30min,0.1M缓冲液充分漂洗,1%锇酸固定30min,缓冲液漂洗,30%酒精开始梯度脱水,醋酸己戊酯过渡5min,临界点干燥,将玻片取出用导电胶粘贴在标本台上,离子溅射镀膜;扫描电境观察拍照。2. Scanning electric field identification: centrifuge the collected suspension cells, remove 2/3 of the supernatant, and resuspend the cells; aspirate the cell suspension, carefully drop it on the glass slide covered with the film, and place it in a petri dish to stand still 30min, then add 2.5% glutaraldehyde to the petri dish, immerse the slides in it, fix for 30min, rinse with 0.1M buffer, fix with 1% osmic acid for 30min, rinse with buffer, start gradient dehydration with 30% alcohol, Hexamyl acetate was transitioned for 5 min, and the critical point was dry. The glass slide was taken out and pasted on the specimen table with conductive glue, and ion sputtered coating; scanning electric field observation and photographing.
透射电境鉴定:细胞离心得到细胞团块,4%戊二醛固定2h(前固定),0.1M磷酸缓冲液漂洗。1%锇酸后固定2h,0.1M磷酸缓冲液漂洗,30%乙醇开始梯度脱水;丙酮、树脂置换及浸透,包埋及聚合,修块切片,醋酸铀、柠檬酸铅染色;透射电境观察拍照。如图1(B、D所示)ES复合诱导剂诱导成熟的DC表面树枝状突起长而多,有大量褶皱,表现出粗细、大小、长短等不一的树枝状,有的突起比较直,有的比较弯曲,布满整个细胞周围,细胞表面不光滑,凸凹不平。符合典型的成熟DC的形态特征。Transmission electric field identification: cell pellets were obtained by centrifugation, fixed with 4% glutaraldehyde for 2 h (prefixed), and rinsed with 0.1 M phosphate buffer. After fixation in 1% osmic acid for 2h, rinsed with 0.1M phosphate buffer, gradient dehydration with 30% ethanol; acetone, resin replacement and infiltration, embedding and polymerization, trimming section, uranyl acetate, lead citrate staining; transmission electric observation Photograph. As shown in Figure 1 (B and D), the mature DCs induced by ES composite inducers have long and numerous dendrites on the surface, with a large number of folds, showing dendrites with different thickness, size and length, some of which are relatively straight. Some are more curved, covering the entire cell, and the cell surface is not smooth and uneven. Consistent with the morphological characteristics of typical mature DCs.
如图1(A、C所示)为未经诱导剂诱导的未成熟DC细胞。Figure 1 (A, C) shows immature DC cells without inducers.
3、DC疫苗流式鉴定3. Flow cytometric identification of DC vaccine
用流式细胞术检测成熟DC和未成熟DC细胞CD86的表达(图2E,B),CD11c是髓源性DC的特征性表面分子,CD11c+表明所提取的细胞为髓源性的,而不是来源于淋巴系统。未成熟的和成熟的DC都高表达CD11c(图2A,D),而成熟的DC比未成熟的表达MHC-II(图2F,C)和CD86的量更高。The expression of CD86 in mature DC and immature DC cells was detected by flow cytometry (Fig. 2E,B), CD11c is a characteristic surface molecule of myeloid-derived DC, and CD11c+ indicates that the extracted cells are myeloid-derived, not the source in the lymphatic system. Both immature and mature DCs highly expressed CD11c (Fig. 2A,D), whereas mature DCs expressed higher amounts of MHC-II (Fig. 2F,C) and CD86 than immature counterparts.
实验例2.猪旋毛虫病免疫治疗Experimental example 2. Immunotherapy of swine trichinosis
1.ES复诱导剂诱导DC疫苗减虫率1. ES complex inducer induces DC vaccine deworming rate
按2000条旋毛虫(旋毛虫国际编号ISS534)/头分别感染健康猪40头,分别以生理盐水、DC、ES和ES复诱导剂诱导DC疫苗治疗感染旋毛虫猪各10头;猪每100Kg体重使用量为1ml;40 healthy pigs were infected with 2000 Trichinella worms (Trichinella International No. ISS534)/head, respectively, and 10 pigs were infected with Trichinella by induction of DC vaccine with normal saline, DC, ES and ES complex inducers respectively; every 100Kg body weight of pigs The usage amount is 1ml;
免疫策略:在感染后,分别于感染后第0天、第2天单倍免疫剂量DC疫苗免疫所有治疗猪,第7天双倍剂量免疫治疗猪,第13天、第17天双倍剂量免疫治疗猪;Immunization strategy: After infection, all treated pigs were immunized with DC vaccine at a single dose on day 0 and 2, double-dose immunization on day 7, and double-dose immunization on day 13 and 17. treatment of pigs;
于18天后剖杀各组猪,以消化法收集各组猪肌肉及肠道旋毛虫并计数,并按以下公式计算减虫率结果见表1。After 18 days, the pigs of each group were slaughtered, and the muscle and intestinal Trichinella worms of each group of pigs were collected and counted by digestion method, and the insect reduction rate was calculated according to the following formula. The results are shown in Table 1.
减虫率=(生理盐水治疗组旋毛虫平均数-治疗组旋毛虫平均数)/生理盐水治疗组旋毛虫平均数Reduction rate = (average number of trichinella in saline treatment group - average number of trichinella in treatment group)/average number of trichinella in saline treatment group
表1 ES复诱导剂诱导DC疫苗减虫率Table 1 Deworming rate of DC vaccine induced by ES complex inducer
2.旋毛虫ES复合诱导剂诱导DC对猪血液细胞因子的调控2. The regulation of porcine blood cytokines by DC induced by Trichinella ES complex inducer
按2000条旋毛虫(旋毛虫国际编号ISS534)/头分别感染健康猪40头,分别以生理盐水、DC、ES和ES复诱导剂诱导DC疫苗治疗感染旋毛虫猪各10头,猪每100Kg体重使用量为1ml;分别于3、6、9、12、15、18、21、24、27天前腔静脉采血按照eBioscience试剂盒说明书,对血清中的细胞因子的变化情况进行ELISA检测。40 healthy pigs were infected with 2000 Trichinella worms (Trichinella International No. ISS534)/head, respectively, and 10 pigs were infected with Trichinella by induction of DC vaccine with normal saline, DC, ES and ES complex inducers respectively, and each pig was 100Kg body weight. The amount used was 1 ml; blood was collected from the vena cava before 3, 6, 9, 12, 15, 18, 21, 24, and 27 days respectively, and the changes of cytokines in serum were detected by ELISA according to the instructions of the eBioscience kit.
免疫效果评价:Immune effect evaluation:
各种细胞因子的变化情况如图4所示。代表旋毛虫免疫反应的IL-6(图3B)、IL-4(图3C)和IL-10(图3D)的表达量下调,IFN-γ(图3A)上调。The changes of various cytokines are shown in Figure 4. The expression levels of IL-6 (Fig. 3B), IL-4 (Fig. 3C) and IL-10 (Fig. 3D) representing the immune response of Trichinella spiralis were down-regulated, and IFN-γ (Fig. 3A) was up-regulated.
实验例3.金丝桃素和喜树碱浓度筛选Experimental example 3. Screening of hypericin and camptothecin concentrations
将金丝桃素和喜树碱按照8μg/mL、1.6μg/mL、0.32μg/mL、0.064μg/mL六个浓度组风别和猪胎儿成纤维细胞(G418)作用,每个浓度设置24h、48h、72h三个时间组,并设置溶剂对照孔和空白孔,每组设3个平行孔。将对细胞有5%毒性的药物浓度(即细胞存活率为95%时的药物浓度)作为该药物对细胞的基本无毒浓度,用24h时的此浓度进行后续试验。细胞存活率=(OD值实验组-OD值对照组)/(OD值对照组-OD值空白组)×100%。结果见图4和图5。Hypericin and camptothecin were treated with porcine fetal fibroblasts (G418) in six concentration groups of 8 μg/mL, 1.6 μg/mL, 0.32 μg/mL, 0.064 μg/mL, and each concentration was set for 24 hours. , 48h, 72h three time groups, and set up solvent control wells and blank wells, each group set up 3 parallel wells. The drug concentration with 5% toxicity to cells (ie, the drug concentration when the cell viability rate is 95%) was taken as the substantially non-toxic concentration of the drug to cells, and the subsequent experiments were carried out with this concentration at 24 h. Cell survival rate=(OD value experimental group-OD value control group)/(OD value control group-OD value blank group)×100%. The results are shown in Figures 4 and 5.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910742898.2A CN110420322B (en) | 2019-08-12 | 2019-08-12 | Trichinella ES compound inducer-induced DC vaccine for the prevention, treatment and diagnosis of swine trichinosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910742898.2A CN110420322B (en) | 2019-08-12 | 2019-08-12 | Trichinella ES compound inducer-induced DC vaccine for the prevention, treatment and diagnosis of swine trichinosis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110420322A true CN110420322A (en) | 2019-11-08 |
CN110420322B CN110420322B (en) | 2023-04-14 |
Family
ID=68415767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910742898.2A Active CN110420322B (en) | 2019-08-12 | 2019-08-12 | Trichinella ES compound inducer-induced DC vaccine for the prevention, treatment and diagnosis of swine trichinosis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110420322B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113186160A (en) * | 2021-04-25 | 2021-07-30 | 大连大学 | Continuous cell line of porcine DC cells and establishment method and application thereof |
CN117018018A (en) * | 2023-10-09 | 2023-11-10 | 吉林大学 | Application of yeast-derived beta-glucan in preparation of medicines for preventing, treating or assisting in treating trichinosis |
CN117050980A (en) * | 2023-10-12 | 2023-11-14 | 吉林大学 | Application of Ts-TTPA antigen in preparation of early diagnosis reagent for trichinosis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5541075A (en) * | 1993-02-05 | 1996-07-30 | Heska Corporation | Carbohydrate-based vaccine and diagnostic reagent for trichinosis |
US20210393681A1 (en) * | 2020-06-22 | 2021-12-23 | Therapeutic Solutions International, Inc. | Treatment of SARS-CoV-2 with Dendritic Cells for Innate and/or Adaptive Immunity |
-
2019
- 2019-08-12 CN CN201910742898.2A patent/CN110420322B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5541075A (en) * | 1993-02-05 | 1996-07-30 | Heska Corporation | Carbohydrate-based vaccine and diagnostic reagent for trichinosis |
US20210393681A1 (en) * | 2020-06-22 | 2021-12-23 | Therapeutic Solutions International, Inc. | Treatment of SARS-CoV-2 with Dendritic Cells for Innate and/or Adaptive Immunity |
Non-Patent Citations (5)
Title |
---|
JING DING ET AL.: "Murine hepatoma treatment with mature dendritic cells stimulated by Trichinella spiralis excretory/secretory products", 《PARASITE》 * |
ROBINSON K ET AL.: "Vaccination against the nematode Trichinella spiralis in high- and low-responder mice. Effects of different adjuvants upon protective immunity and immune responsiveness", 《IMMUNOLOGY.》 * |
刘菁: "旋毛虫ES抗原诱导DC对肝细胞癌预防性作用的实验研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
周玲等主编: "《感染性疾病的处置策略与防治》", 30 June 2017, 吉林科学技术出版社 * |
路丽群: "旋毛虫病ELISA和PCR诊断方法的建立", 《万方数据知识服务平台》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113186160A (en) * | 2021-04-25 | 2021-07-30 | 大连大学 | Continuous cell line of porcine DC cells and establishment method and application thereof |
CN117018018A (en) * | 2023-10-09 | 2023-11-10 | 吉林大学 | Application of yeast-derived beta-glucan in preparation of medicines for preventing, treating or assisting in treating trichinosis |
CN117050980A (en) * | 2023-10-12 | 2023-11-14 | 吉林大学 | Application of Ts-TTPA antigen in preparation of early diagnosis reagent for trichinosis |
Also Published As
Publication number | Publication date |
---|---|
CN110420322B (en) | 2023-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108103017B (en) | Isolation and purification method of human umbilical cord mesenchymal stem cell exosomes and application of human umbilical cord mesenchymal stem cell exosomes | |
CN110420322B (en) | Trichinella ES compound inducer-induced DC vaccine for the prevention, treatment and diagnosis of swine trichinosis | |
CN105198988A (en) | Anti-vibrio brilliant yolk antibody and preparation method thereof | |
Nazari et al. | Comparison of the Th1, IFN-γ secreting cells and FoxP3 expression between patients with stable graft function and acute rejection post kidney transplantation | |
CN113616674A (en) | Application of an extracellular vesicle with anti-inflammatory effect | |
Chai et al. | Role of intraepithelial lymphocytes in mucosal immune responses of mice experimentally infected with Cryptosporidium parvum | |
CN106075429B (en) | Goat pox, sheep pox and aphtha triple cell attenuated vaccine and preparation method and application thereof | |
CN109294989B (en) | Method for separating and primary culturing grass carp dendritic cells | |
CN105688206A (en) | Application of paecilomyces cicadae cordyceps polysaccharides in preparation of chicken immunity enhancement reagent | |
CN106519058A (en) | Flarnmulina velutipes polysaccharide and preparation method thereof | |
CN111117964B (en) | A kind of tumor-derived exosome and its preparation method and use | |
Mohamed et al. | The use of probiotics to enhance immunity of broiler chicken against some intestinal infection pathogens | |
KR101950008B1 (en) | Method of preparing tolerogenic cells and insulin producing cells based diabetes and obesity vaccine | |
CN102793712A (en) | Application of chrysin in preparation of medicaments for treating autoimmune and inflammatory diseases | |
WO2016201658A1 (en) | Method for preparing tumor specific ctls | |
CN109954139B (en) | Application of matrine as immunoadjuvant in preparation of gastric cancer dendritic cell vaccine | |
CN118290563A (en) | Prostate cancer antigen peptide and immunoadjuvant composition and application thereof in resisting tumor | |
CN113583957B (en) | Preparation method of pig alveolar macrophages | |
CN104357393A (en) | Isolated culture method of chicken intestinal tract epithelial GammaDeltaT cells | |
CN110343656A (en) | A kind of separation method of Procambius clarkii blood lymphocyte | |
CN107090434B (en) | Blood anticoagulation and preservation method for improving CIK cell culture effect | |
Alishahi et al. | Effects of Aloe vera crude extract on growth performance and some hemato-immunological indices of Oncorhynchus mykiss in farm scale. | |
CN106265621B (en) | Dimethyl fumarate prevents and treats the application in graft versus host disease(GVH disease) and Graft versus leukemia drug in preparation | |
CN101934073B (en) | Bovine viral diarrhea virus (BVDV) transgenosis astragalus mongholicus vaccine and production method | |
Gao et al. | Effects of inactivated porcine epidemic diarrhea virus on porcine monocyte-derived dendritic cells and intestinal dendritic cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |